Browse the evidence

Orforglipron, an oral non-peptide GLP-1 receptor agonist, produces clinically significant, dose-dependent reductions in body weight, HbA1c, systolic blood pressure, and atherogenic lipids (LDL, VLDL, triglycerides) with high consistency across trials.

Orforglipron is an oral medication that helps reduce weight, blood sugar, blood pressure, and bad cholesterol. It works by mimicking a gut hormone (GLP-1). You take one pill a day. It can cause stomach issues like nausea, but doctors can help manage this by starting with a low dose and increasing it slowly. It is designed for people with obesity or type 2 diabetes who want to avoid injections.

Triple receptor agonists (retatrutide) produce the highest magnitude of weight loss reported to date in pharmacotherapy for obesity, surpassing dual and single GLP-1 agonists.

Retatrutide is currently the most effective drug for weight loss in this class, working by targeting three hormonal pathways (GLP-1, GIP, and glucagon). It is administered once weekly. Expect significant weight loss, but also expect gastrointestinal side effects like nausea during the initial weeks, which typically subside.

Intragastric balloons (Obalon, Orbera, ReShape Duo) provide temporary weight loss (12-25% EWL) when combined with lifestyle modifications.

Intragastric balloons are temporary devices placed in the stomach to help with weight loss. They work by taking up space, making you feel full sooner. Clinical trials show they can lead to 12-25% excess weight loss when combined with lifestyle changes, significantly outperforming lifestyle changes alone. They require an endoscopic procedure and are typically removed after 6 months.

Tirzepatide (10 mg and 15 mg) provides statistically superior weight reduction and waist circumference reduction compared to semaglutide (2.4 mg) and liraglutide (3 mg) in patients with obesity or overweight without type 2 diabetes.

For patients with obesity or overweight without type 2 diabetes, Tirzepatide (10mg and 15mg doses) administered once weekly, alongside lifestyle changes, achieves significantly greater weight loss and waist circumference reduction than Semaglutide (2.4mg) or Liraglutide (3mg). The safety profile is generally comparable across all three treatments.

Incretin polyagonists (dual and triple agonists) produce weight loss and metabolic improvements comparable to, or approaching, those of bariatric surgery, serving as a potent non-surgical alternative.

If you have obesity and want significant weight loss without surgery, incretin polyagonists (like tirzepatide or retatrutide) are now a viable, highly effective medical option. They work by mimicking gut hormones to reduce appetite and improve metabolism. While they require weekly injections (or soon, oral pills), they can achieve weight loss results similar to bariatric surgery. Expect some initial stomach upset, which usually fades as your body adjusts. Consult a doctor to see if you are a candidate.

Preservation of lean mass during GLP-1/GIP-induced weight loss requires high-quality protein distribution (1.2–1.5 g/kg/day) and resistance exercise to mitigate sarcopenia and maintain oncologic treatment tolerance.

To prevent muscle loss while on GLP-1/GIP drugs, eat 1.2–1.5 grams of protein per kilogram of body weight daily, spread across meals, and engage in regular resistance exercise.

Lifestyle interventions involving ≥150 minutes of exercise per week combined with caloric restriction are associated with the highest odds of long-term weight loss maintenance (5-10%).

To keep weight off long-term, aim for at least 150 minutes of exercise per week, ideally closer to 275 minutes, while maintaining a healthy diet. This combination offers the best chance of keeping 5-10% of your weight off permanently.

GLP-1 receptor agonists (semaglutide, tirzepatide) induce significant weight loss and reduce systemic inflammation through both weight-dependent mechanisms and direct anti-inflammatory effects on cytokines (TNF-α, IL-6, CRP) and gut microbiota composition.

GLP-1 agonists like semaglutide and tirzepatide are highly effective for weight loss and reducing inflammation. They work by mimicking a gut hormone to increase satiety and slow digestion, while also directly lowering inflammatory markers. These are prescription medications requiring weekly injections, typically starting at a lower dose and titrating up to minimize side effects.

GLP-1 receptor agonists (liraglutide, semaglutide, tirzepatide) significantly reduce the progression to type 2 diabetes and improve normoglycemia in prediabetic individuals, with effects partially sustained after withdrawal.

For individuals with prediabetes, GLP-1 receptor agonists like liraglutide, semaglutide, and tirzepatide are effective in preventing type 2 diabetes and restoring normal blood sugar levels. While some benefits may diminish after stopping the medication, the initial reduction in diabetes risk is significant.

Incretin-based pharmacotherapy (specifically GLP-1 and GLP-1/GIP agonists like semaglutide and tirzepatide) is effective for significant weight loss and cardiovascular risk reduction in obesity, but discontinuation leads to rapid weight regain and loss of cardiometabolic benefits, necessitating long-term or lifelong therapy.

Incretin drugs like semaglutide and tirzepatide are highly effective for weight loss and heart health, but they are not a cure. If you stop taking them, you will likely regain the weight and lose the heart benefits. Therefore, these medications should be viewed as a long-term or lifelong treatment for obesity, combined with lifestyle changes, rather than a short-term fix.

Tirzepatide at maximum tolerated dose (MTD) is more cost-effective and clinically superior to semaglutide at MTD for weight management in US adults with obesity or overweight, resulting in lower total healthcare costs, higher quality-adjusted life years (QALYs), and reduced incidence of type 2 diabetes and cardiovascular disease.

For US adults with obesity or overweight, tirzepatide at its maximum tolerated dose is a more effective and cost-saving option than semaglutide. It leads to greater weight loss, fewer cases of diabetes and heart disease, and significant long-term healthcare cost savings, making it a superior clinical and economic choice when combined with diet and exercise.

GLP-1 receptor agonists (semaglutide) and dual agonists (tirzepatide) are clinically effective for glycemic control and significant weight loss, with tirzepatide demonstrating superior magnitude of weight loss compared to semaglutide in head-to-head trials.

GLP-1 and dual agonists are highly effective for weight loss and blood sugar control. Tirzepatide generally produces greater weight loss than semaglutide. However, high costs and insurance restrictions (often requiring prior failure of other drugs like metformin) limit access. Discuss cardiovascular benefits if you have existing heart disease.

Tirzepatide treatment (10-15 mg once weekly) significantly improves waist-to-height ratio (WHtR) categories compared to placebo, with 54.7% of participants improving their WHtR category at 72 weeks versus 9.6% on placebo.

If you have obesity or overweight with related health complications, treatment with tirzepatide (10-15 mg weekly) combined with lifestyle changes significantly improves your waist-to-height ratio, a key marker for cardiometabolic risk, far more effectively than placebo. This suggests a substantial reduction in central adiposity.

Tirzepatide produced a mean weight loss of −7.14 kg in individuals without diabetes and −5.87 kg in individuals with type 2 diabetes (T2D).

Tirzepatide may be an effective option for weight management in both diabetic and non-diabetic obese adults.

Supplementation with Vicia faba protein hydrolysate (VFH) at a low dose of 2.4g/day significantly enhances leg strength and muscular endurance beyond resistance training alone in healthy, untrained adults.

Take 2.4g of Vicia faba protein hydrolysate daily with your first meal while doing resistance training 3 times a week. This specific supplement has been shown to improve leg strength and endurance more than training alone, even without increasing your total protein intake.

Vicia faba protein hydrolysate (VFH) supplementation significantly increases Bone Mineral Content (BMC) compared to placebo when combined with resistance training.

If you are concerned about bone health, this specific supplement taken with resistance training may help increase bone mineral content, showing a 0.7% increase over 8 weeks.

Older adults require approximately 0.40 g/kg of high-quality protein per meal to maximize muscle protein synthesis, which is nearly double the 0.24 g/kg threshold sufficient for young adults.

To build or maintain muscle as you age, you cannot rely on the standard 'one size fits all' protein recommendation. You must eat roughly 0.4 grams of high-quality protein (like meat, eggs, or whey) for every kilogram of your body weight at each meal. For most people, this means aiming for 25-30 grams of protein per meal, spread evenly throughout the day, rather than eating most of your protein at dinner.

Resistance training is the primary intervention to restore anabolic sensitivity in aging muscle, with effects lasting 24-48 hours post-exercise.

To combat age-related muscle loss, you must engage in resistance training (lifting weights or using resistance bands) at least a few times a week. This exercise temporarily 'resensitizes' your muscles to protein, making your meals more effective at building muscle. The benefit lasts for about 24-48 hours, so consistency is key.

Creatine monohydrate supplementation provides additive benefits to resistance training in older adults by increasing intramuscular phosphocreatine stores and enhancing high-intensity exercise capacity.

If you are doing resistance training, adding creatine monohydrate is one of the most effective ways to get more out of your workouts. It helps your muscles produce energy for high-intensity efforts, allowing you to train harder and build more muscle over time.

Complementing habitual diet with a mixed plant-based protein blend (soy/pea) yields equivalent resistance training-induced muscle mass and strength gains compared to animal-based protein (whey) in healthy young men.

If you are doing resistance training, you do not need to buy whey protein to build muscle. You can use a blend of plant proteins (like soy and pea) instead. Take 15 grams of this blend three times a day with your main meals. This will help you gain muscle and strength just as well as animal protein, provided you are eating enough total protein and training consistently.

Resistance training combined with adequate protein intake (approx. 1.6 g/kg/day) maximizes muscle protein synthesis and hypertrophy by activating the mTORC1 pathway, whereas chronic mTOR hyperactivation without balance contributes to metabolic disease.

To maximize muscle growth, engage in resistance training and consume approximately 1.6 grams of protein per kilogram of body weight daily. Distribute this protein evenly across your meals, aiming for about 0.25 g/kg per meal if you are younger, or 0.40 g/kg per meal if you are older to overcome age-related anabolic resistance. Prioritize high-quality, leucine-rich protein sources like whey. To support long-term metabolic health, balance this anabolic focus with periodic AMPK activation through intermittent fasting or aerobic exercise.

An additional daily protein intake of 1 g/kg from supplements, resulting in a total daily intake of approximately 2 g/kg, is most effective for enhancing athletic performance.

Aim for a total daily protein intake of about 2 g/kg of body weight. If you eat enough protein from food, you may not need supplements. If you use supplements, adding 1 g/kg/day of protein powder is likely the optimal amount for performance gains.

Individualized nutritional rehabilitation, including whey protein (10g 3x/day), fish oil, and vitamin D supplementation combined with resistance training, significantly improves muscle strength, cognitive function, and quality of life in elderly patients with sarcopenia and cognitive impairment compared to standard care.

For elderly patients with both muscle loss and cognitive decline, a standard diet and exercise plan is often insufficient. A specialized program combining high-quality whey protein (10g, 3 times daily), Omega-3s with Vitamin D, and targeted resistance training, managed by a multidisciplinary team, significantly improves strength, thinking skills, and daily living ability. This approach requires more resources but yields superior functional outcomes for this vulnerable population.

Beta-alanine supplementation increases intramuscular carnosine levels by 40-80% over 4-6 weeks, which buffers hydrogen ions during high-intensity exercise to delay fatigue in efforts lasting 1-4 minutes.

If you do short, intense cycling efforts (1-4 minutes), take 3.2-6.4g of beta-alanine daily for at least 4 weeks. Expect some tingling, which is harmless. This will help you delay fatigue in those specific efforts.